167 related articles for article (PubMed ID: 15645676)
1. Quantitative NAT for pathogen inactivation verification.
McKenney K; Gillmeister L; Marlowe K; Armistead D; Burgess W; Drohan W
Dev Biol (Basel); 2004; 118():81-8. PubMed ID: 15645676
[TBL] [Abstract][Full Text] [Related]
2. Virus inactivation and protein recovery in a novel ultraviolet-C reactor.
Wang J; Mauser A; Chao SF; Remington K; Treckmann R; Kaiser K; Pifat D; Hotta J
Vox Sang; 2004 May; 86(4):230-8. PubMed ID: 15144527
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
4. Cell culture-based assay of parvovirus B19 and the relevance of animal model viruses.
Blümel J
Dev Biol (Basel); 2004; 118():107-12. PubMed ID: 15645679
[TBL] [Abstract][Full Text] [Related]
5. Verification and validation of diagnostic laboratory tests in clinical virology.
Rabenau HF; Kessler HH; Kortenbusch M; Steinhorst A; Raggam RB; Berger A
J Clin Virol; 2007 Oct; 40(2):93-8. PubMed ID: 17766174
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
Sawyer L; Hanson D; Castro G; Luckett W; Dubensky TW; Stassinopoulos A
Transfusion; 2007 Jun; 47(6):1062-70. PubMed ID: 17524098
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment.
Hourfar MK; Schmidt M; Seifried E; Roth WK
Vox Sang; 2005 Aug; 89(2):71-6. PubMed ID: 16101686
[TBL] [Abstract][Full Text] [Related]
8. International standardization of gene amplification technology.
Robertson JS
Biologicals; 1998 Jun; 26(2):111-3. PubMed ID: 9811515
[TBL] [Abstract][Full Text] [Related]
9. Amplification and subtraction methods and their application to the discovery of novel human viruses.
Muerhoff AS; Leary TP; Desai SM; Mushahwar IK
J Med Virol; 1997 Sep; 53(1):96-103. PubMed ID: 9298739
[No Abstract] [Full Text] [Related]
10. Theoretical considerations on viral inactivation or elimination.
Willkommen H; Löwer J
Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
[No Abstract] [Full Text] [Related]
11. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
[No Abstract] [Full Text] [Related]
12. Effects of probe binding mutations in an assay designed to detect parvovirus B19: implications for the quantitation of different virus genotypes.
Baylis SA; Fryer JF; Grabarczyk P
J Virol Methods; 2007 Jan; 139(1):97-9. PubMed ID: 17045660
[TBL] [Abstract][Full Text] [Related]
13. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
14. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses.
Mani B; Gerber M; Lieby P; Boschetti N; Kempf C; Ros C
Transfusion; 2007 Oct; 47(10):1765-74. PubMed ID: 17880601
[TBL] [Abstract][Full Text] [Related]
16. Qualification of virus/cell systems for their intended use.
Gröner A
Dev Biol (Basel); 2004; 118():55-63. PubMed ID: 15645673
[No Abstract] [Full Text] [Related]
17. Prevalence of Parvovirus B19 and Hepatitis A virus in Portuguese blood donors.
Henriques I; Monteiro F; Meireles E; Cruz A; Tavares G; Ferreira M; Araújo F
Transfus Apher Sci; 2005 Nov; 33(3):305-9. PubMed ID: 16203176
[TBL] [Abstract][Full Text] [Related]
18. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
19. Contamination with PCR detectable virus in a virus isolation quality assurance panel.
Gunson RN; Abraham E; Carman WF
J Virol Methods; 2006 Oct; 137(1):150-1. PubMed ID: 16860403
[TBL] [Abstract][Full Text] [Related]
20. Methods for validation of hepatitis B virus inactivation.
Gerlich WH; Glebe D
Dev Biol (Basel); 2004; 118():113-22. PubMed ID: 15645680
[No Abstract] [Full Text] [Related]
[Next] [New Search]
